文献速递糖尿病

生长抑素在小鼠中介导GLP-1抑制胰高血糖素分泌的作用

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice.
PubMed 文献 · Diabetologia · 2017-05-27

该研究利用灌流小鼠胰腺模型探讨GLP-1抑制胰高血糖素分泌的机制。结果显示GLP-1在6.0、1.5和0.5 mmol/l葡萄糖浓度下均显著抑制胰高血糖素分泌,且伴随生长抑素分泌增加;阻断生长抑素受体2可完全消除GLP-1的抑制作用。结论认为GLP-1的降胰高血糖素作用完全由生长抑素旁分泌介导,但该模型中低血糖时抑制作用仍保留,体内如何避免此现象尚待解答。

要点

  • 灌流小鼠胰腺中GLP-1在6.0、1.5和0.5 mmol/l葡萄糖下均显著抑制胰高血糖素分泌。
  • GLP-1抑制胰高血糖素的同时生长抑素分泌增加,阻断生长抑素受体2可完全消除该抑制。
  • 该模型中低血糖时GLP-1的抑制作用仍保留,体内如何避免低血糖时过度抑制尚不清楚。

核心结论

  • 在灌流小鼠胰腺中,GLP-1的降胰高血糖素作用完全由生长抑素的旁分泌作用介导。
  • 该模型中GLP-1在低血糖水平仍保留抑制胰高血糖素的作用,接受GLP-1受体激动剂治疗的个体在体内如何避免此现象尚待解答。

研究设计与样本

  • 研究采用灌流小鼠胰腺模型验证假说:GLP-1不抑制低血糖时的胰高血糖素分泌,因为该抑制依赖生长抑素分泌,而生长抑素分泌依赖葡萄糖水平。

主要发现

  • GLP-1在6.0、1.5和0.5 mmol/l葡萄糖下均显著抑制胰高血糖素分泌,分别降低27.0%、37.1%和23.6%。
  • 上述抑制均伴随生长抑素分泌增加,分别增加286.8%、158.7%和118.8%。
  • 特异性阻断生长抑素受体2使胰高血糖素分泌增加:1.5 mmol/l葡萄糖下增加118.8%,6.0 mmol/l葡萄糖下增加162.9%。
  • 特异性阻断生长抑素受体2完全消除了GLP-1的抑制效应。

局限性

  • 该研究使用灌流小鼠胰腺模型,在该模型中GLP-1在低血糖水平仍保留抑制胰高血糖素的作用,接受GLP-1受体激动剂治疗的个体在体内如何避免此现象尚待解答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon-like peptide-1 (GLP-1) receptor agonists are currently used for the treatment of type 2 diabetes. Their main mechanism of action is enhancement of glucose-induced insulin secretion (from increased beta cell glucose sensitivity) and inhibition of glucagon secretion. The latter has been demonstrated to account for about half of their blood glucose-lowering activity. Whereas the effect of GLP-1 on insulin secretion is clearly dependent on ambient glucose concentrations and has been described in detail, the mechanism responsible for the inhibitory effect of GLP-1 on glucagon secretion is heavily debated. Glucagon inhibition is also said to be glucose-dependent, although it is unclear what is meant by this. We hypothesise here that GLP-1 does not inhibit glucagon secretion during hypoglycaemia because the inhibition depends on somatostatin secretion, which in turn is dependent on glucose levels. METHODS: We used the perfused mouse pancreas model to investigate this hypothesis. RESULTS: We found that, in this model, GLP-1 was able to significantly inhibit glucagon secretion from pancreatic alpha cells at all glucose levels tested: 6.0, 1.5 and 0.5 mmol/l (-27.0%, -37.1%, and -23.6%, respectively), and the decrease in glucagon secretion was invariably accompanied by an increase in somatostatin secretion (+286.8%, +158.7%, and +118.8%, respectively). Specific blockade of somatostatin receptor 2 increased glucagon secretion (+118.8% at 1.5 mmol/l glucose and +162.9% at 6.0 mmol/l glucose) and completely eliminated the inhibitory effect of GLP-1. CONCLUSIONS/INTERPRETATION: We have shown here that the glucagon-lowering effect of GLP-1 is entirely mediated through the paracrine actions of somatostatin in the perfused mouse pancreas. However, in this model, the inhibitory effect of GLP-1 was preserved at hypoglycaemic levels, leaving unanswered the question of how this is avoided in vivo in individuals treated with GLP-1 receptor agonists.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Ørgaard A, Holst JJ. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia. 2017. PMID: 28551699. doi:10.1007/s00125-017-4315-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。